Search research articles
Contact Us
Filters
Showing results (1-10 of 7) with videos related to
Page
of 1
Sort By:
Statistics in Medicine
|
November 27, 2004
Two-part statistics with paired data
C Bascoul-Mollevi, S Gourgou-Bourgade, A Kramar
Revue D'Epidemiologie Et De Sante Publique
|
April 18, 2015
[Editorial]
R Giorgi, S Gourgou-Bourgade, M-C Picot
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 31, 2009
A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802)
M Ychou, J-L Raoul, J-Y Douillard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 30, 2017
Late toxicities and clinical outcome at 5 years of the ACCORD 12/0405-PRODIGE 02 trial comparing two neoadjuvant chemoradiotherapy regimens for intermediate-risk rectal cancer
D Azria, J Doyen, M Jarlier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 30, 2014
Guidelines for time-to-event end point definitions in sarcomas and gastrointestinal stromal tumors (GIST) trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†
C A Bellera, N Penel, M Ouali, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 16, 2015
Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)
S Gourgou-Bourgade, D Cameron, P Poortmans, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 1, 2015
Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†
S Gourgou-Bourgade, D Cameron, P Poortmans, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 7) with videos related to
Sort By:
Page
of 1
Statistics in Medicine
|
November 27, 2004
Two-part statistics with paired data
C Bascoul-Mollevi, S Gourgou-Bourgade, A Kramar
Revue D'Epidemiologie Et De Sante Publique
|
April 18, 2015
[Editorial]
R Giorgi, S Gourgou-Bourgade, M-C Picot
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 31, 2009
A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802)
M Ychou, J-L Raoul, J-Y Douillard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 30, 2017
Late toxicities and clinical outcome at 5 years of the ACCORD 12/0405-PRODIGE 02 trial comparing two neoadjuvant chemoradiotherapy regimens for intermediate-risk rectal cancer
D Azria, J Doyen, M Jarlier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 30, 2014
Guidelines for time-to-event end point definitions in sarcomas and gastrointestinal stromal tumors (GIST) trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†
C A Bellera, N Penel, M Ouali, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 16, 2015
Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)
S Gourgou-Bourgade, D Cameron, P Poortmans, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 1, 2015
Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†
S Gourgou-Bourgade, D Cameron, P Poortmans, et al.
Page
of 1